EYE vs MVP

ASX Healthcare sector comparison — updated 14 Jul 2026 — Healthcare sector

EYE

NOVA EYE FPO [EYE]

57MEDIUM

MVP

MEDICALDEV FPO [MVP]

57MEDIUM

Score Breakdown

EYE MVP
Technical
57
37
Catalyst
53
54
Sentiment
50
50
Fundamental
76
95
Momentum
39
49
Risk Gate
45
50

Key Metrics

EYE Metric MVP
$32.8MMarket Cap$45.6M
269KAvg Volume (20d)136K
N/AShort InterestN/A
$0.20552-Week High$0.765
$0.10052-Week Low$0.365
+0.0%Daily Change+0.0%
$0.115Reference Price$0.405
-42.4%ROE-0.8%
-21.3%Profit Margin-1.1%

Active Signals

EYE Signals

●MACD momentum is picking up steam
●Stochastic is stretched into overbought — could need a breather
●Volatility is contracting — like a spring being compressed, breakouts often follow
●Below the 200-day average — the long-term trend is still working against it
●Low cash runway (2 quarters) - dilution risk
●Low P/S ratio (1.0x)
●Strong revenue growth (+29%)
●EPS estimates revised upward (+10pts)

MVP Signals

●MACD crossed bearish — momentum is fading
●Drifting lower — down 6.9% over the last 5 days
●Beating the Small Ords index — relative strength of 1.15, so it's outpacing the pack
●Below the 200-day average — the long-term trend is still working against it
●Cash positive / operating cashflow positive
●4C filed 2026-04-23
●Low P/S ratio (1.1x)
●Moderate revenue growth (+8%)

Ask Scout AI to compare EYE and MVP in depth.

Open Scout AI →

Track both stocks and 2,200+ more — Free

Daily AI-powered screening across every ASX small cap.

Open Screener

Related Comparisons

CGS vs EYE →CGS vs MVP →AHC vs CMP →AHC vs ARX →AHC vs EYE →
EYE Full Analysis → MVP Full Analysis → Healthcare Sector → All Comparisons →
GENERAL INFORMATION ONLY. SmallCapData provides algorithmic screening data and does not constitute personal financial advice, a recommendation, or an offer to buy or sell any security. This content is produced by an algorithm, not a licensed financial adviser. You should consider seeking independent financial advice before making any investment decision. Past performance is not indicative of future results. Trading in small-cap securities carries a high degree of risk, including the risk of total loss of capital. The author may hold positions in mentioned securities. SmallCapData does not hold an Australian Financial Services Licence (AFSL).